María José Galindo Puerto

8PUBLICATIONS
59CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityTraditional, complementary and integrative medicine not elsewhere classifiedMajor global burdens of diseaseDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 24, 2026
Immune Trajectories After Switch to Long-Acting Cabotegravir Plus Rilpivirine in the RELATIVITY Cohort.

|Oct 23, 2026
Long-term Effectiveness, Treatment Persistence, and Timing of Virological Failure With Long-Acting Cabotegravir Plus Rilpivirine in Real-World HIV Care: RELATIVITY Cohort.

|Sep 17, 2026
Quality of life among older adults with HIV after switching to bictegravir-based three-drug or dolutegravir-based two-drug regimens.

|Dec 17, 2025
Lack of association between loneliness, social isolation and inflammation in people living with HIV aged ≥50 years: Results from the sub-study "No One Alone-Gesida Study".

Jose-Ramon Blanco, Helena Albendin-Iglesias, Eugenia Negredo-Puigmal

|Jul 25, 2025
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002-2023).

Juan Berenguer, Chiara Fanciulli, María M Arcos

|Dec 16, 2024
Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.

Darrell H S Tan, Andrea Antinori, Beng Eu

Pageof 2

Frequent Collaborators

3 joint publications

Noemí Cabello-Clotet

3 joint publications

Luis Enrique Morano

3 joint publications

María Jesús Vivancos

2 joint publications

Juan Emilio Losa